The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

Abstract excerpt

Abstract Purpose: EGFR exon 19 deletion (Ex19Del) mutations account for approximately 60% of lung cancer–associated EGFR mutations and include a heterogeneous group of mutations. Although they are associated with benefit from tyrosine kinase inhibitors (TKI), the relative inhibitor sensitivity of individual Ex19Del mutations is unknown. Experimental Design: We studied the TKI sensitivity and structural features...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
• Share to Lung Cancer Diagnosis and Treatment
• Share to Lung Cancer Treatments and Mutations